Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Interest & Investment Income (2017 - 2025)

Protagonist Therapeutics' Interest & Investment Income history spans 9 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 1.34% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $28.8 million, up 9.4%, while the annual FY2025 figure was $28.8 million, 9.4% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $6.8 million at Protagonist Therapeutics, down from $7.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.7 million in Q3 2024 and bottomed at $97000.0 in Q2 2021.
  • The 5-year median for Interest & Investment Income is $4.1 million (2023), against an average of $3.7 million.
  • The largest annual shift saw Interest & Investment Income tumbled 80.61% in 2021 before it surged 1745.08% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $122000.0 in 2021, then soared by 1745.08% to $2.3 million in 2022, then skyrocketed by 88.45% to $4.2 million in 2023, then soared by 61.55% to $6.9 million in 2024, then dropped by 1.34% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Interest & Investment Income are $6.8 million (Q4 2025), $7.0 million (Q3 2025), and $7.4 million (Q2 2025).